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Abstract
Background: Type-2 diabetes rates in First Nations communities are 3-5 times higher than the general Canadian
population, resulting in a high burden of disease, complications and comorbidity. Limited community nursing
capacity, isolated environments and a lack of electronic health records (EHR)/registries lead to a reactive, disorganized
approach to diabetes care for many First Nations people. The Reorganizing the Approach to Diabetes through the
Application of Registries (RADAR) project was developed in alignments with federal calls for innovative, culturally
relevant, community-specific programs for people with type-2 diabetes developed and delivered in partnership with
target communities.
Methods: RADAR applies both an integrated diabetes EHR/registry system (CARE platform) and centralized care
coordinator (CC) service that will support local healthcare. The CC will work with local healthcare workers to support
patient and community health needs (using the CARE platform) and build capacity in best practices for type-2 diabetes
management. A modified stepped wedge controlled trial design will be used to evaluate the model. During the
baseline phase, the CC will work with local healthcare workers to identify patients with type-2 diabetes and register
them into the CARE platform, but not make any management recommendations. During the intervention phase, the
CC will work with local healthcare workers to proactively manage patients with type-2 diabetes, including monitoring
and recall of patients, relaying clinical information and coordinating care, facilitated through the shared use of
the CARE platform. The RE-AIM framework will provide a comprehensive assessment of the model.
The primary outcome measure will be a 10% improvement in any one of A1c, BP, or cholesterol over the baseline values.
Secondary endpoints will address other diabetes care indicators including: the proportion of clinical measures completed
in accordance with guidelines (e.g., foot and eye examination, receipt of vaccinations, smoking cessation counseling); the
number of patients registered in CARE; and the proportion of patients linked to a health services provider. The cost-
effectiveness of RADAR specific to these communities will be assessed. Concurrent qualitative assessments will provide
contextual information, such as the quality/usability of the CARE platform and the impact/satisfaction with the model.
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Discussion: RADAR combines innovative technology with personalized support to deliver organized diabetes care in
remote First Nations communities in Alberta. By improving the ability of First Nations to systematically identify and track
diabetes patients and share information seamlessly an overall improvement in the quality of clinical care of First Nations
people living with type-2 diabetes on reserve is anticipated.
Trial registration: ISRCTN study ID ISRCTN14359671, retrospectively registered October 7, 2016.
Keywords: First Nations, Diabetes, Electronic Health Record, Care Coordinator, Registry
Background
It is well known that type-2 diabetes disproportionally
impacts Indigenous/First Nations people across the world,
including Canada [1]. Overall, the prevalence of type-2
diabetes in First Nations communities is 3–5 times higher
than in the general Canadian population [2, 3]. First
Nations populations experience a high burden of disease,
complications, and comorbidity [1], which is compounded
by suboptimal care in isolated or remote communities
[4–6]. Moreover, First Nations communities consistently
rank among the lowest on social determinants of health,
eroding their capacity to adopt health-promoting con-
ditions, navigate the health system and advocate for
change [7].
Integral to the delivery of organized diabetes care
are the 5R’s: Register (systematically tracking all patients);
Relay (facilitate information sharing); Recall (timely re-
view and reassessment); Recognize (screening/risk factors
assessment); and Resource (support self-management)
[8]. In Canada, there is a shift towards a more compre-
hensive chronic care model (CCM) [8], including in
the management of type-2 diabetes. However, most
people living in First Nations communities have limited
access to regular primary care and specialist services
required for CCM-consistent diabetes care [9], with
most care delivered through federally funded, nurse-
led homecare and community health programs [10].
Perhaps due to fragmented care, along with cultural
and geographical barriers, and physician/nursing short-
ages in rural and remote communities, First Nations
populations have poor diabetes-related outcomes, includ-
ing high rates of dialysis, blindness, amputations and
foreshortened life expectancy [3, 6].
Despite recognition of these barriers, transformations
to improve type-2 diabetes care and outcomes among
First Nations people have been slow. Systematic proactive
organization of diabetes care for First Nations people with
diabetes living on reserves is lacking in Canada [2].
Current practice guidelines and Aboriginal Diabetes
Initiative’s in Canada call for innovative, culturally relevant
approaches that rely on community-specific programs for
people with type-2 diabetes developed and delivered in
partnership with target communities [2, 8].
Information systems that allow for a comprehensive-
based approach to care, such as electronic health records
(EHRs) linked with diabetes registries, positively impact
quality of diabetes care and reduce costs [11–13]. Further-
more, incorporation of professional support to fully lever-
age the infrastructure, through a care coordinator, has been
shown to improve intermediate measures of cardiometa-
bolic care (e.g., A1c, blood pressure, cholesterol) and many
other processes of care (e.g., foot and eye care, chronic care
coordination) compared to usual care, however delivered
[9, 11–16]. Currently, few First Nations communities have
the infrastructure, expertise, or resources to employ the
5R’s as part of their CCM based quality improvement strat-
egies, particularly the foundation upon which all these
efforts are built: the ability to systematically identify and
track diabetes patients and share information seamlessly
(i.e., Register, Relay, Recall). Thus, it is unknown whether
these benefits apply to the Canadian context and specific-
ally to remote, isolated and under-resourced First Nations
communities. This is context for which the “Reorganizing
the Approach to Diabetes through the Application of
Registries” (RADAR) project was designed.
Objectives
Our purpose is to describe the RADAR project. Our pri-
mary objective is to implement and assess the effective-
ness of an integrated population based electronic health
record (EHR)/registry system specifically designed for
First Nations communities (Community Assessment Re-
sponse and Empowerment [CARE] platform), coupled with
dedicated support from a centralized care coordinator
(CC) to systematically organize proactive diabetes care in
the communities to improve diabetes-related outcomes.
Thus, RADAR is the combination of the CARE platform
and the CC support. We hypothesize that RADAR will
result in an overall improvement in the quality of clinical
care of First Nations people living with type-2 diabetes
on reserve, as measured by evidence-based outcomes
(A1c, BP, cholesterol) and quality of care indicators (e.g.
foot and eye examinations). We believe that RADAR
will help promote timely management of people with
type-2 diabetes and increase diabetes knowledge and
management practices among local healthcare workers
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[15, 17]. In addition, managers can use the EHR/registry
to track diabetes trends, determine the effectiveness of
diabetes programs, and assist in resource planning.
Methods
Model overview
The RADAR model incorporates two distinct elements:
1) an EHR, integrated with a population-based diabetes
registry and analytics platform – CARE platform; and, 2)
a centralized care coordinator. The CARE platform was
designed by OKAKI Health Intelligence Inc. to meet the
specific requirements of nursing-driven health programs
currently being delivered on reserve in Canadian First
Nations communities. Major limitations of existing EHRs,
which are largely designed for physician offices, are:
misalignment with programs, reporting and professional
practice needs of service providers on reserve; no
population-based registry that supports sharing between
facilities and population (as well as individual) measure-
ment and chronic disease management; and cost [18, 19].
The first element of RADAR, the CARE platform,
specifically integrates a patient registry and electronic
clinical chart for patients across three traditionally distinct
and segregated programs responsible for care on reserves
(Home and Community Care, Aboriginal Diabetes Initia-
tive, and Community Health); thereby, improving coord-
ination of care between service providers on reserve. The
CARE platform includes a diabetes registry, enabling
the systematic, standardized capture of patient data on
key diabetes outcomes and quality of care indicators
(e.g., A1c, BP, cholesterol, foot and eye exams); and incor-
porates performance-based measurement and reporting
on clinical care standards and targets at both the popula-
tion and individual level. The system also provides
real-time recognition and recall of patients needing
follow-up care. Moreover, the CARE platform uses a
simple interface and can be accessed through a web-based
portal allowing for remote monitoring and evaluation of
care and reporting.
In our ongoing discussions with community leaders,
most diabetes care tends to be reactive to clients seeking
care rather than proactively in accordance with clinical
practice guidelines. Many clients do not receive ongoing
diabetes care and do not have a regular general practi-
tioner who coordinates care. Thus, we have combined
our CARE platform with a key facilitator – a centralized
care coordinator (CC). The CC is ideally a First Nations
registered nurse and certified diabetes educator with
significant experience with care on reserve. The CC will
work remotely with the local healthcare workers on
reserve to improve quality of care for people with diabetes,
facilitated through shared use of the CARE platform
and web conferencing technologies. The CC supports
systematic review of patients and case conferencing
activities to support and prioritize care, problem-solves
system or patient-level care issues, and provides education
to local healthcare workers. In addition, the CC acts as a
bridge between the First Nations communities and other
service providers to help coordinate patient care on and
off reserve. Together, both RADAR elements address the
5Rs in organizing diabetes care, that is, recognize, register,
relay, recall, and resource, in the First Nations context. In
addition, managers and researchers can use the analysis of
population-level data for epidemiological assessments,
quality-improvement, and decision-making.
Setting
RADAR involves collaboration with several First Nations
communities in Alberta, representing separate treaty
areas across the province (continuous expansion of the
RADAR model to additional First Nations communities
is ongoing). We estimate that approximately 1000 people
with type-2 diabetes currently reside in the pilot com-
munities. All communities involved are several hours of
travel from a major urban center, where the majority of
diabetes specialist care services are located. Some com-
munities have local family physician clinics, located just
off reserve that also provide care for patients with dia-
betes; other communities have visiting family physicians
on one or more days a week; while other communities
have no local physician services, although services are
available in neighboring rural communities. As a result,
local, on-reserve, healthcare workers are the primary ser-
vice providers delivering diabetes care and general health
services for these populations. Prior to implementing
RADAR, all communities were familiar with the CARE
platform for the management of patient care within their
respective communities.
Outcomes
The primary outcome will be a 10% improvement in
measures over the baseline control periods in any one of
the following: A1c, BP, cholesterol. This is consistent
with our previous Canadian work that considers a 10%
improvement in any of these measures to be the minim-
ally clinically important difference [20]. For patients who
are already at ‘target’ for any or all three measures at
baseline, we will consider persistence at target (i.e.,
maintain values within 10% of baseline) as also achieving
the primary outcome. Secondary endpoints will address
other areas of diabetes care and process indicators
compared to baseline including: the proportion of clin-
ical measures and tasks completed in accordance with
Canadian Diabetes Association Clinical Practice guidelines
(e.g., A1c, BP, cholesterol, foot and eye examination,
receipt of vaccinations, smoking cessation counseling);
the number of patients registered in CARE; and the
proportion of patients linked to a health services provider.
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In addition, we are collecting detailed information to
conduct a comprehensive economic evaluation, asses-
sing the cost-effectiveness of RADAR specific to these
communities. Our approach to the economic analysis
will be analogous to methods previously published by
our group [21, 22].
We will also conduct a qualitative assessment as part
of our comprehensive evaluation to supplement the
primary and secondary quantitative assessments. The
purpose of the qualitative component is to provide
contextual information, such as the quality/usability of
the CARE platform and the impact/satisfaction of local
healthcare workers with the CC model.
Eligibility and recruitment
Participation in RADAR is dictated by the Health Dir-
ector and leadership within each First Nations commu-
nity health facility. After agreeing to participate, local
healthcare workers (e.g., Health Center, Healing Center)
will actively register First Nations patients with diabetes
into the CARE platform. All patients in the community
are eligible to be included in the CARE platform; however,
patients must meet the following criteria to be evaluated
within RADAR:
a) Inclusion criteria: Patients diagnosed with type-2
diabetes; recently (within last 1-2 years) received
care from the First Nations health facility; provided
verbal consent for First Nations health care workers
to manage their diabetes.
b) Exclusion criteria: Patients with type-1 diabetes;
patients <18 years of age; those who are subsequently
discovered not to have type-2 diabetes; those refusing
care within the First Nations health facility; patients
with type-2 diabetes identified after the conclusion of
the baseline phase of the project.
Implementation and evaluation
The implementation and evaluation of RADAR is segre-
gated into two distinct parts. OKAKI Health Intelligence
Inc., who has a long history of working with First Na-
tions communities in the province, will implement
RADAR, including the CARE platform and care coord-
ination. Researchers from the University of Alberta will
independently evaluate the effectiveness of RADAR. By
separating the implementation from the evaluation, we
believe a more robust evaluation will be achieved. To
ensure a robust evaluation, a modified stepped wedge
controlled implementation trial design will be employed.
This design is a highly valid cross-over design, whereby
each community serves as its own control before ‘switch-
ing’ to the intervention at different time points [23, 24]. In
essence, RADAR will be implemented sequentially to the
communities in consecutive 4–6 month periods, based on
the communities ‘readiness’. By the end of the evaluation




Once a community has been allocated to begin RADAR,
the community will enter into an initial 6-month pro-
spective baseline phase. During the baseline phase, the
CC will work with the local healthcare workers to
recognize all known patients with diabetes through
existing medical records and histories, ad-hoc registries,
etc. All newly identified patients with type-2 diabetes dis-
covered during the baseline phase will also be included.
Once identified, all patients will be registered into the
CARE platform, including their demographic and clinical
data (e.g., A1c, blood pressure, lipids, eye exams, foot
care), where available. Patient information to populate the
baseline data will be obtained from all potential sources
(e.g., medical records, patient interviews, Alberta’s provin-
cial EHR for laboratory results (Netcare)). All available
data up to 18 months prior to the end of the baseline
period will be used to populate the CARE platform, as
patient encounters with the health system may not be
consistent. Patients identified with type-2 diabetes follow-
ing the conclusion of the baseline phase will be included
in the CARE platform and process of care coordination
but will not be included in analyses, as no baseline control
phase will be available for these patients. Importantly,
although the CC will work with the local healthcare
workers to recognize and register patients with type-2
diabetes, the CC will not make care management recom-
mendations during the baseline phase.
Intervention phase
After completion of the Baseline Phase, each community
will transition into the intervention phase for a mini-
mum of 1 year. The intervention phase will conclude
on December 31, 2020, for all communities and length
of follow-up is dependent on timing of initiation of
RADAR within the community. During the intervention
phase, the CC will help the local healthcare workers to
proactively manage patients with type-2 diabetes, in-
cluding monitoring and recall of patients, relaying clinical
information and coordinating care, facilitated through
shared use of the CARE platform and web conferencing
technologies. In addition, the CC will provide support on
the use of the CARE platform and training and education
for the local healthcare workers on ‘best practices’ for the
management of type-2 diabetes. It is expected that the
local healthcare workers’ reliance on the CC will diminish
over time, as they become more confident and competent
using the CARE platform and in their diabetes knowledge
and ability to manage patients, leading to sustainability.
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Evaluation design
We will conduct a comprehensive evaluation of RADAR,
using the RE-AIM framework [25]. We have used this
framework to evaluate other diabetes-related, quality-
improvement interventions [26]. RE-AIM consists of five
dimensions: Reach into the target population; Effective-
ness of the intervention; Adoption by targeted end-users;
Implementation, including consistency and cost of delivery;
and Maintenance of intervention effects over time [25]
Table 1.
Thus, our comprehensive evaluation will include both
quantitative and qualitative components. We will use the
quantitative data for the clinical outcomes mentioned
above as part of our overall assessment of the dimension
of effectiveness. The primary source of qualitative data
includes interviews during the baseline, intervention and
post intervention phases. We will use purposeful sampling
to identify key informants with expert knowledge of the
implementation of RADAR in each community (e.g. the
CC, local healthcare workers, and health directors). All
interviews will take place at community health facilities or
via videoconferencing, using semi-structured interview
guides. The purpose of the interviews is to document the
organization of existing type-2 diabetes care within each
community, implementation facilitators, barriers, and
lessons learned, perceived appropriateness of RADAR
for the communities, and the overall usability and accept-
ance of the technology (i.e., CARE platform). In addition,
the software vender will also capture changes made to the
software over time as requested by the communities. The
interviews will be digitally recorded for subsequent analysis,
transcribed verbatim by an independent transcriptionist,
and verified for accuracy. All qualitative data sources (e.g.
validated baseline assessments and interview transcripts)
will be compiled and managed using Atlas.ti 7 software.
Data analysis
For quantitative data, all relative changes will be analyzed
using the last known recorded value from the CARE plat-
form from baseline to the end of the intervention phase.
We will employ an intention-to-treat analysis, whereby all
patients who are enrolled and have baseline data will be
Fig. 1 RADAR Stepped-Wedge Design
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included in our primary analysis. The primary endpoint
(i.e., 10% improvement in any of A1c, BP, cholesterol
values from baseline or those maintaining values within
10% of baseline if at any or all three targets at baseline)
will be evaluated using a conventional intention to treat
analysis with logistic regression. However, if the observed
intracluster correlation coefficient (ICC) is non-ignorable,
we will use generalized estimating equations (GEE) that
accounts for the clustered and hierarchical nature of our
data [24]. Several a-priori subgroup analyses are planned
for the primary endpoint. First, we will restrict analyses to
patients not at target for any of the 3 primary outcome
measures. Second, we will restrict analyses to those pa-
tients who were at target for each primary outcome meas-
ure (A1c, BP, cholesterol) to fully examine persistence at
target over time. Additional subgroups of interest include
analyses stratified by sex, and analyses stratified by age
(<65 vs > =65 years). Secondary endpoints include: the
proportion of clinical measures completed in accordance
with guidelines (e.g., A1c, BP, cholesterol, foot and eye
examination, receipt of vaccinations, smoking cessation
counseling); the number of patients registered in CARE;
and the proportion of patients linked to a health services
provider.
We anticipate not having complete quantitative data
on all endpoints of interest, given the real-world imple-
mentation of the project. Several approaches will be used
for missing clinical data. First, in alignment with the
intention-to-treat approach, we will use the baseline
observation carried forward technique for our primary
outcome. The stability of the results will be additionally
evaluated using the multiple imputation method as a
sensitivity analysis.
For qualitative data analysis, we will use an integrated
approach. First, we will use the RE-AIM framework as
the initial coding structure. Second, we will use an
inductive approach [27] to identify emerging codes and
concepts within each dimension using conventional
approaches [28–30]. We will employ several verification
strategies to ensure the reliability and validity of the
qualitative results including methodological coherence,
appropriate sampling, collecting and analyzing data
concurrently [31], and debriefing [30].
Power and sample size
In prior studies, about 40% of diabetes patients will have
at least a 10% improvement in A1c, BP, and cholesterol
over time when studied under ‘usual care’[32]. To detect
at least an additional 10% improvement in the propor-
tion of patients achieving our primary endpoint under
the RADAR model (i.e., move the population from 40%
achieving endpoint to at least 50% achieving endpoint),
at an alpha =0.05, an ICC of 0.01, we require 1153
total patients to detect a clinically important difference
with 80% power. Assuming a 10% loss to follow-up, we
require approximately 1250 total patients among our
communities.
Discussion
It is well known that diabetes care is suboptimal in First
Nations populations [4–6]. Our own research [20, 32],
coupled with other large-scale research projects across
the country, has clearly demonstrated the need for im-
proved care in this high-risk population [5, 6]. We will
evaluate the effectiveness of RADAR in improving the
quality of care for First Nations people with type-2
diabetes living on reserve. The aim of RADAR is to im-
prove processes of care, and ultimately clinical outcomes
in patients, and to build local capacity and expertise in the
management of diabetes. The current Canadian Diabetes
Association Clinical Practice Guidelines strongly advocate
for multidisciplinary teams to improve outcomes in people
with diabetes [8], yet these multidisciplinary teams are
often lacking in First Nations communities [5]. We believe
RADAR, including the CARE platform and CC model,
can facilitate a culturally relevant community-based multi-
disciplinary team approach to diabetes care.
There are several strengths related to our implementa-
tion and evaluation of RADAR. First, the RADAR model
is well positioned to succeed in the communities based
on prior work by our team. OKAKI Health Intelligence
Inc. has been successfully working in First Nations com-
munities in the province for over 7 years. This partnership
reinforces that RADAR is community-specific, culturally
relevant and promotes its sustainability. Moreover, the
communities have already adopted the CARE platform for
other aspects of patient care (e.g., home care). Therefore,
Table 1 RADAR Structure by the RE-AIM Framework
RE-AIM dimension Brief definition of dimension Approach Data source(s)
Adoption Willingness of community members to initiate an intervention Qualitative approach Document review
Reach Into the target population(s) (e.g., First Nations members with T2D) Quantitative approach Registry/CARE analytics
Implementation Intervention is implemented as intended, and consistently across
communities
Qualitative approaches Interviews, document review,
field notes
Effectiveness Determined by outcomes Quantitative approach Registry/CARE analytics
Interviews
Maintenance Intervention effects or sustainability over time Qualitative approach Document review
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the extension of the CARE platform to chronic disease
management is highly feasible.
Second, our use of the RE-AIM framework will pro-
vide insight into the broader impact of RADAR beyond
clinical effectiveness and identify both facilitators and
barriers to implementing RADAR within each community.
These results will help inform scale and spread of RADAR
to other suitable communities and populations.
Third, we will employ a valid stepped wedge study de-
sign. Often quality-improvement projects show benefit
when evaluated, but are conducted without a robust com-
parison group, making assessment of the true absolute
improvements in care difficult to decipher. By including
control periods over time, we will be able to elucidate any
improvements directly attributed to the RADAR model.
Regardless, there are design features of RADAR that
warrant further discussion. First, we have used process
(i.e., intermediate or surrogate) outcomes as measures of
quality, rather than harder clinical endpoints (e.g. diabetic
complications like amputation, heart attack or stroke). We
chose these process endpoints, as we do not expect to
observe changes in hard clinical outcomes over the short
timeline of this project. Nevertheless, reductions in these
outcomes (e.g. A1c, BP, cholesterol, etc.) are well estab-
lished in many large scale RCTs as conferring substantial
benefits on either macro- or microvascular outcomes and
are recommended in the Canadian Diabetes Association
Clinical Practice Guidelines [8, 32]. Moreover, our object-
ive is to determine if RADAR can influence these clinical
measures, not reaffirm if these changes are important on
hard clinical endpoints. If the intervention improves these
outcomes, hard clinical endpoints would be expected to
also change (e.g. heart attacks and stroke) over time.
Second, our economic models cannot be fully popu-
lated by our results. This is true of most models and
we will need to make assumptions based on literature
and expert opinion. However, our proposed economic
approach is peer-reviewed and published and we have
used it in previous analogous analyses [21, 22]. We will
also undertake many sensitivity analyses to demonstrate
the results are robust and valid.
Last, we have designed a pragmatic and feasible con-
trolled project rather than a randomized controlled effi-
cacy trial. Our project is a community-based intervention
aimed at the local healthcare workers as opposed to pa-
tients per se. Individual patients could not be randomized
to care with and without RADAR because of the threat
of “contamination” (i.e., patients within a community
health facility would likely be exposed to some aspects
of the intervention regardless of study arm). Similarly,
randomization could not occur at the level of the local
healthcare workers for similar reasons (e.g., increased
knowledge on the appropriate care of patients with dia-
betes would be expected to diffuse throughout the entire
care team in a health facility). Moreover, acceptance of a
community to a traditional randomized control trial would
be expected to be low, as few communities would be
accepting of being the control community for extended
durations. The stepped wedge design will be morally and
politically more acceptable to the communities, and be-
cause of logistical, practical, and financial constraints, it
can be better implemented in stages. Furthermore, the
proposed design incorporates a number of methods other
than random allocation to protect internal validity (e.g.,
controlled before after with sequential roll-out to reduce
time-related biases), and the design is considered valid
and included in the Cochrane EPOC Systematic Reviews.
The results from our project may have greater applicability
than the results of a randomized trial in a highly selected
and potentially biased sample.
Conclusion
RADAR combines innovative technology with personal-
ized support to deliver organized diabetes care in remote
First Nations communities in Alberta. The project is
novel as it involves public, academia and private sector
partnerships to improve care for First Nations people
with type-2 diabetes. By design, our integrated EHR/
registry connects all personnel/facilities and enables real
time analysis at community and system levels. Moreover,
care coordination typically refers to a single person in
the community to oversee care, which would be difficult
to replicate or build capacity for all First Nations commu-
nities. In our innovative approach, the local healthcare
workers and centralized CC will work together to support
patient and community health needs, using technology to
support communication. Thus, each healthcare worker
focuses on his or her own strengths, connections and cap-
acity to improve care. Moving forward, hopefully RADAR,
in combination with other similar initiatives, may bridge
the gap between First Nations health and the general
population, and reduce diabetes-related morbidity and
premature mortality.
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